William Blair analyst Brandon Vazquez has maintained their bullish stance on EW stock, giving a Buy rating on August 19.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Edwards Lifesciences’ strategic positioning and growth potential. The company’s proactive investment in the asymptomatic TAVR market, ahead of a potential CMS reimbursement decision, suggests a forward-thinking approach that could lead to significant market advantages. Although the current patient volumes for asymptomatic cases are not substantial, the anticipation of a CMS NCD update by late 2025 and subsequent coverage in 2026 positions Edwards Lifesciences to benefit uniquely from this approval.
Furthermore, the company’s TMTT segment, particularly the Evoque system, is progressing as expected, despite some concerns about real-world safety data. Management’s commitment to long-term goals, including operating margin expansion and double-digit EPS growth, underscores a robust financial outlook. With the stock trading at a multiple of 29.5 times the 2026 EPS estimate, Vazquez maintains an optimistic view, reinforcing the Outperform rating for Edwards Lifesciences.
In another report released on August 19, RBC Capital also maintained a Buy rating on the stock with a $89.00 price target.
Based on the recent corporate insider activity of 102 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year.